Archief Roodbont

The hills are alive with discussion of the most exciting development in cardiovascular medicine this year: the emergence of novel anticoagulants that may well replace the "gold standard" that has been in place for 50 years. In the coming year as many as 3 new agents may be available to consider as alternatives to warfarin and aspirin for the prevention of stroke in patients who have atrial fibrillation. The implications for anticoagulation therapy are enormous. Drs. Garcia, Alexander, Mahaffey, and Wallentin discuss aspects of RE-LY, AVERROES, ROCKET AF, and ARISTOLE, all pivotal trials either completed or soon to be completed in the quest for a better and easier to use anticoagulant for preventing stroke in patients who have atrial fibrillation.